New antibody therapy targets Hard-to-Treat prostate cancer
NCT ID NCT07529717
First seen Apr 25, 2026 · Last updated May 15, 2026 · Updated 4 times
Summary
This early-stage study tests an experimental drug called AZD8359 in 42 adults with metastatic prostate cancer that has worsened despite prior treatments. The drug is designed to help the immune system attack cancer cells. The study aims to find the safest and most effective dose by first testing different doses in a small group, then expanding to a larger group.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for METASTATIC PROSTATE CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Research Site
Orlando, Florida, 32809, United States
-
Research Site
East Brunswick, New Jersey, 08816, United States
-
Research Site
Hackensack, New Jersey, 07601, United States
-
Research Site
Providence, Rhode Island, 02903, United States
-
Research Site
Darlinghurst, 2010, Australia
-
Research Site
Melbourne, 3000, Australia
-
Research Site
Seoul, 03722, South Korea
-
Research Site
Seoul, 06351, South Korea
Conditions
Explore the condition pages connected to this study.